Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study

(2018) Andrew M. Blumenfeld et al.   JOURNAL OF HEADACHE AND PAIN

Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study

(2017) Richard B. Lipton et al.   HEADACHE

Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design

(2017) Daniel Serrano et al.   JOURNAL OF HEADACHE AND PAIN

Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study

(2016) Richard B. Lipton et al.   HEADACHE

Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies

(2016) Serena L. Orr et al.   HEADACHE

Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine

(2015) Andrew M. Blumenfeld et al.   BMC Neurology

Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example

(2015) David W. Dodick et al.   JOURNAL OF PAIN

Functional Alterations of Pain Processing Pathway in Migraine Patients with Cutaneous Allodynia

(2015) Ning Chen et al.   PAIN MEDICINE

Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine

(2014) Regina Rendas-Baum et al.   Health and Quality of Life Outcomes

The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients

(2012) Regina Rendas-Baum et al.   QUALITY OF LIFE RESEARCH

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program

(2011) Sheena K. Aurora et al.   HEADACHE

Thalamic sensitization transforms localized pain into widespread allodynia

(2010) Rami Burstein et al.   ANNALS OF NEUROLOGY

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

(2010) SK Aurora et al.   CEPHALALGIA

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

(2010) HC Diener et al.   CEPHALALGIA

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

(2010) David W. Dodick et al.   HEADACHE

Minimal Important Differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1

(2009) JC Cole et al.   CEPHALALGIA

Global prevalence of chronic migraine: A systematic review

(2009) JL Natoli et al.   CEPHALALGIA

Topiramate Treatment of Chronic Migraine: A Randomized, Placebo-Controlled Trial of Quality of Life and Other Efficacy Measures

(2009) Stephen Silberstein et al.   HEADACHE

Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults

(2008) S Silberstein et al.   CEPHALALGIA

Prevalence and characteristics of allodynia in headache sufferers: A population study

(2008) M. E. Bigal et al.   NEUROLOGY

Cutaneous allodynia in the migraine population

(2007) Richard B. Lipton et al.   ANNALS OF NEUROLOGY